<?xml version='1.0' encoding='UTF-8'?>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Neurol</journal-id><journal-id journal-id-type="pmc-domain-id">48</journal-id><journal-id journal-id-type="pmc-domain">bmcneul</journal-id><journal-title-group><journal-title>BMC Neurology</journal-title></journal-title-group><issn pub-type="epub">1471-2377</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11484424</article-id><article-id pub-id-type="pmcid-ver">PMC11484424.1</article-id><article-id pub-id-type="pmcaid">11484424</article-id><article-id pub-id-type="pmcaiid">11484424</article-id><article-id pub-id-type="pmid">39420261</article-id><article-id pub-id-type="doi">10.1186/s12883-024-03904-9</article-id><article-id pub-id-type="publisher-id">3904</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Investigating the association between the GAP-43 concentration with diffusion tensor imaging indices in Alzheimer’s dementia continuum</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ariaei</surname><given-names initials="A">Armin</given-names></name><address><email>arminaraee@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ghorbani</surname><given-names initials="A">Atousa</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Habibzadeh</surname><given-names initials="E">Elham</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moghaddam</surname><given-names initials="N">Nazanin</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chegeni Nezhad</surname><given-names initials="N">Negar</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abdoli</surname><given-names initials="A">Amirabbas</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mazinanian</surname><given-names initials="S">Samira</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sadeghi</surname><given-names initials="M">Mohammad</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mayeli</surname><given-names initials="M">Mahsa</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03w04rv71</institution-id><institution-id institution-id-type="GRID">grid.411746.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 4911 7066</institution-id><institution>School of Medicine, </institution><institution>Iran University of Medical Science, </institution></institution-wrap>Hemmat Highway, Next to Milad Tower, Tehran, 1449614535 Iran </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01c4pz451</institution-id><institution-id institution-id-type="GRID">grid.411705.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0166 0922</institution-id><institution>Advanced Diagnostic and Interventional Radiology Research Center (ADIR), </institution><institution>Tehran University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.411463.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 0706 2472</institution-id><institution>Department of Biology, </institution><institution>Islamic Azad University East Tehran Branch, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04krpx645</institution-id><institution-id institution-id-type="GRID">grid.412888.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2174 8913</institution-id><institution>School of Medicine, </institution><institution>Tabriz University of Medical Science, </institution></institution-wrap>Tabriz, Iran </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00j1sp553</institution-id><institution-id institution-id-type="GRID">grid.469938.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0494 2580</institution-id><institution>Department of Clinical Biochemistry, </institution><institution>Islamic Azad University Shahrood Branch, </institution></institution-wrap>Shahrood, Iran </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01kzn7k21</institution-id><institution-id institution-id-type="GRID">grid.411463.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 0706 2472</institution-id><institution>Department of Advanced Sciences and Technology, </institution><institution>Islamic Azad University Tehran Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.411172.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0081 2808</institution-id><institution>Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences, </institution><institution>Centre Hospitalier Universitaire de Sherbrooke (CHUS), Université de Sherbrooke, </institution></institution-wrap>Sherbrooke, Canada </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.464598.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0417 696X</institution-id><institution>Department of Psychology, </institution><institution>Islamic Azad University Semnan Branch, </institution></institution-wrap>Semnan, Iran </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01c4pz451</institution-id><institution-id institution-id-type="GRID">grid.411705.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0166 0922</institution-id><institution>School of Medicine, </institution><institution>Tehran University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>24</volume><issue-id pub-id-type="pmc-issue-id">452029</issue-id><elocation-id>397</elocation-id><history><date date-type="received"><day>12</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>4</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>10</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>17</day><month>10</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-19 07:25:28.910"><day>19</day><month>10</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>© The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12883_2024_Article_3904.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Synaptic degeneration, axonal injury, and white matter disintegration are among the pathological events in Alzheimer’s disease (AD), for which growth-associated protein 43 (GAP-43) and diffusion tensor imaging (DTI) could be an indicator. In this study, the cerebrospinal fluid (CSF) GAP-43 clinical trajectories and their association with progression and AD hallmarks with white matter microstructural changes were evaluated.</p></sec><sec><title>Methods</title><p id="Par2">A total number of 133 participants were enrolled in GAP-43 and DTI values were compared between groups, both cross-sectionally and longitudinally with two and four-year follow-ups. Subsequently, the correlation between GAP-43 levels in the CSF and DTI values was investigated using Spearman’s correlation.</p></sec><sec><title>Results</title><p id="Par3">The CSF level of GAP-43 is negatively correlated with the mean diffusivity measures in Fornix (Cres)/Stria terminals in early and late MCI (r<sub>s</sub>=-0.478 <italic toggle="yes">p</italic> = 0.021 and r<sub>s</sub>=-0.425 <italic toggle="yes">p</italic> = 0.038). Additionally, the CSF level of GAP-43 is negatively correlated with fractional anisotropy in the cingulum in late MCI (r<sub>s</sub>=-0.437 <italic toggle="yes">p</italic> = 0.033). Moreover, the axial diffusivity in superior corona radiate (r<sub>s</sub>=-0.562 <italic toggle="yes">p</italic> = 0.005 and r<sub>s</sub>=-0.484 <italic toggle="yes">p</italic> = 0.036) and radial diffusivity in superior fronto-occipital fasciculus was negatively correlated with GAP-43 level in the early and mid-MCI participants (r<sub>s</sub>=-0.520 <italic toggle="yes">p</italic> = 0.011 and r<sub>s</sub>=-0.498 <italic toggle="yes">p</italic> = 0.030).</p></sec><sec><title>Conclusions</title><p id="Par4">Presynaptic marker GAP-43 in combination with DTI can be used as a novel biomarker to identify microstructural synaptic degeneration in the early MCI. In addition, it can be used as a biomarker for tracking the progression of AD and monitoring treatment efficacy.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12883-024-03904-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alzheimer's disease</kwd><kwd>Biomarker</kwd><kwd>GAP-43</kwd><kwd>DTI</kwd><kwd>MCI</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© BioMed Central Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Worldwide, the incidence of dementia is increasing due to the increasing number of elderly. It is estimated that the number of people with dementia will grow 2.6 times between 2019 and 2050 [<xref ref-type="bibr" rid="CR1">1</xref>]. Alzheimer’s disease (AD) is the most common type of dementia, frequently affecting elderly people more than 65 years old throughout the world [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Currently, there are no emerging treatments or approved drugs to reverse, slow, or stop the progressive disease process [<xref ref-type="bibr" rid="CR4">4</xref>–<xref ref-type="bibr" rid="CR7">7</xref>]. Mild cognitive impairment (MCI) is an intermediate state between dementia and normal cognitive aging which is associated with the long-lasting pathological deposition of misfolded proteins and synaptic dysfunction in the brain. One of the greatest obstacles researchers face is MCI classification [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Although some MCI patients appear to remain stable or even improve over time, the majority of them change to AD dementia within five years [<xref ref-type="bibr" rid="CR10">10</xref>]. MCI individuals who develop AD dementia are classified as having progressive MCI, and those who retain their MCI state are classified as having stable MCI [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par6">Cognitive impairment and behavioral changes consequence from neurodegeneration are commonly observed about 10 years after the onset of proteinopathy. The presence of amyloid-β plaques (Aβ) and hyperphosphorylation of self-aggregating tau, which results in neurofibrillary tangles (NFTs), have effects on disease pathologic progression and serve as biomarkers [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Studies have shown that AD-related pathological changes begin long before clinical symptoms appear. It is widely accepted that synaptic loss and dysfunction play a pivotal role in AD and are associated with cognitive decline [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Thus, additional plasma biomarkers reflecting synaptic loss and dysfunction could further enhance differential diagnosis and are useful as outcome markers in clinical trials, providing new information about the stage of the disease, and preventative assessments.</p><p id="Par7">Growth-associated protein 43 (GAP-43) has been known as a phosphoprotein of cerebrospinal fluid (CSF) that is encoded via the GAP-43 gene located in the nervous system [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. GAP-43 is essential for synaptic plasticity, reactive synaptogenesis formation, regulation of axonal outgrowth, and memory and learning functions [<xref ref-type="bibr" rid="CR17">17</xref>]. The expression of presynaptic protein GAP-43 highly increases during synaptogenesis and neuronal development and after that in the hippocampus and associated cortex of the human brain [<xref ref-type="bibr" rid="CR18">18</xref>]. Moderate GAP-43 expression can enhance memory, while overexpression of GAP-43 may cause the dysfunction of neuronal synapses and culminate in loss of memory [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. CSF GAP-43 levels have seldom been researched in AD patients [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Current evidence suggests a substantial increase in the CSF level of GAP-43 in the early stages of AD [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par8">Diffusion Tensor Imaging (DTI) is an MRI-based modality that allows the decoding of the water molecule’s mobility in vivo and provides information about the white matter (WM) changes, synaptic damage, and neurodegeneration in AD patients [<xref ref-type="bibr" rid="CR22">22</xref>–<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par9">Emerging studies point to modifications of WM as a biological marker for pathological importance, which can be a potential target for early-stage dementia [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Early accumulation of CSF and plasma p-tau has been reported in the corpus callosum of a brain with Alzheimer’s pathology, which is also associated with a decline in WM integrity [<xref ref-type="bibr" rid="CR27">27</xref>]. There have been few studies on whether presynaptic CSF GAP-43 is associated with WM microstructure in MCI subjects, owing to the pivotal biomarker role of GAP-43 for AD [<xref ref-type="bibr" rid="CR28">28</xref>]. In the current study, we carried out an evaluation to elucidate the relationship between GAP-43 levels and DTI-detected changes of WM in patients with MCI. Since GAP-43 is recently proposed to have potential biomarker utility in the AD continuum [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], we aimed to investigate where this protein can indicate the microstructural changes in the brain, especially in the early stages of mild cognitive impairment.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Participants and data</title><p id="Par10">Data used in this research was extracted from a longitudinal multicenter study named Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). Since the time the project was initiated the ADNI3 content was not fully completed, the participant data were extracted from the ADNI1, ADNI-GO, and ADNI2 projects. Herein we evaluate a total number of 1269 GAP-43 samples from participants who took lumbar puncture. In addition, a total number of 977 DTI samples were extracted from the database. To perform a comparison between the GAP-43 and DTI values following screening was taken. After a glance at the data, 464 duplicated values for the ID of patients were detected; therefore 804 unique IDs were isolated. To compare DTI data with gap-43 data, datasets were combined based on ID and the year of the sample taken, therefore, 133 values remained. Moreover, to compare the amount of GAP-43 and DTI in different years, IDs containing repetitive GAP-43 values were analyzed separately (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par11">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Patient selection flow chart. Patient data were extracted from ADNI-1, ADNI-GO, and ADNI-2 datasets. Groups indicated by red color were excluded from the analysis</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e456" position="float" orientation="portrait" xlink:href="12883_2024_3904_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec4"><title>CSF GAP-43 measurements</title><p id="Par12">To measure the GAP-43 level in the CSF, in-house ELISA techniques were implemented. The performing procedure is briefly described as follows: admixture of the anti-GAP-43 antibody of the mouse (0.77 µg/ml NM4) with Nunc-Immuno Polysorp microwell modules (Thermo Fisher Scientific, Massachusetts, US) in the pH of 9.6 provided by carbonate buffer in 4 °C temperatures. Moreover, in the measurement procedure, three containers were labeled as CSF, blank, and control samples. Subsequently, the samples were colorized with 3, 3´, 5, 5´-tetramethylbenzidine (TMB, KemEnTech Diagnostics). The color density at 450 nm was measured through a SunriseTM microplate absorbance reader (Tecan Group, Männedorf, Switzerland) by considering a reference value of 650 nm. The C-terminal of GAP-43 was a cue for two mouse monoclonal and polyclonal GAP-43 antibodies; the first was NM4 as a coating antibody, and the second was a polyclonal GAP-43 antibody as a detector antibody. Finally, all laboratory data (1268 samples) were analyzed to determine the exact concentration of GAP-43 indicated by pg/mg in the range of 312 − 20.000 pg/mL. Quality control samples named QC1 and QC2 were taken from patients’ CSF in collaboration with the Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, and Mölndal, Sweden. Detailed information was available in the previously published article [<xref ref-type="bibr" rid="CR14">14</xref>].</p></sec><sec id="Sec5"><title>Imaging data acquisition</title><p id="Par13">The detailed data regarding the DTI protocol were previously mentioned in the Nir et al. 2013 study [<xref ref-type="bibr" rid="CR30">30</xref>]. Whole-brain MRI scanning on 3 Tesla GE Medical Systems scanners was taken from participants and DTI values of participants were derived from raw MRI data according to the ADNI protocol. Besides, to assess the quality of MRI images in finding possible artifacts, visualization was performed. The image acquisition properties for Anatomical T1-weighted SPGR (spoiled gradient echo) sequences were as follows. The flip angle was selected as 11° in a 256 × 256 matrix. The voxel size was selected with the values of 1.0 × 1.0 × 1.2 mm<sup>3</sup>. Moreover, three values for Echo time (TE), Repetition Time (TR), and Inversion time (TI) were selected as 2.85 ms, 6.98 ms, and 400 ms, respectively. Besides, the value for diffusion-weighted images (DWI) was as follows: A matrix size of 256 × 256, total scan time of 9 min, 9000 ms for TR, and voxel size of 2.7 × 2.7 × 2.7 mm<sup>3</sup>. To achieve an improved signal-to-noise ratio, for every DTI scan, 46 images were acquired: 5 T2-weighted images without diffusion sensitization (b0 images), and 41 diffusion-weighted images for which the b-value was set at 1000 s/mm². To ensure quality assurance, all T1-weighted MR, FLAIR, and DWI images underwent a visual review to identify and exclude those with substantial motion, artifacts, or high white matter hyperintensities (± 2.5 standard deviations from the mean in the AD group).</p></sec><sec id="Sec6"><title>Preprocessing steps</title><p id="Par14">Head motion and eddy current distortions were then corrected for each subject’s raw DWI volumes by aligning them to the mean b0 image, the volume without diffusion sensitization, using the FSL tool eddy_correct (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fmrib.ox.ac.uk/fsl">www.fmrib.ox.ac.uk/fsl</ext-link>). In addition, in the T1-weighted anatomical scans, extra-cerebral tissue was roughly removed by employing a range of software packages, with significant processing reliance on ROBEX-an automated program that has been previously trained on manually “skull-stripped” MRI data [<xref ref-type="bibr" rid="CR31">31</xref>] and FreeSurfer [<xref ref-type="bibr" rid="CR32">32</xref>]. The skull-stripped volumes were visually assessed, and the most appropriate one was chosen, occasionally undergoing additional manual editing. Anatomical scans were then subjected to intensity inhomogeneity normalization via the MNI nu_correct tool (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.bic.mni.mcgill.ca/software/">www.bic.mni.mcgill.ca/software/</ext-link>). In addition, non-brain tissue was removed from the DWI through the application of the Brain Extraction Tool (BET) from FSL [<xref ref-type="bibr" rid="CR33">33</xref>]. To achieve alignment of data from different subjects within the same 3D coordinate system, each T1-weighted anatomical image was subjected to linear alignment with a standard brain template, (downsampled Colin27), using FSL flirt [<xref ref-type="bibr" rid="CR34">34</xref>] with six degrees of freedom (dof) to permit translations and rotations in three dimensions. In order to mitigate susceptibility artifacts resulting from echo-planar imaging (EPI), which can produce distortions at tissue-fluid boundaries, skull-stripped b0 images were linearly aligned (FSL flirt with 9 dof) and then elastically registered to their respective T1-weighted structural images via an inverse-consistent registration algorithm that utilized a mutual information cost function [<xref ref-type="bibr" rid="CR35">35</xref>]. Following the generation of the 3D deformation fields, these were applied to the other 41 DWI volumes prior to the assessment of diffusion parameters. To ensure proper alignment of the DWI images with the structural T1-weighted scan, a corrected gradient table was computed.</p></sec><sec id="Sec7"><title>DTI maps</title><p id="Par15">Utilizing FSL dtifit, a single diffusion tensor or ellipsoid was constructed at each voxel in the brain from the DWI scans that had undergone eddy and EPI correction. The eigenvalues of the diffusion tensor (λ1, λ2, λ3) were then used to generate scalar maps of anisotropy and diffusivity, indicating the lengths of the ellipsoid’s longest, middle, and shortest axes. Fractional anisotropy (FA) values were obtained from the following formula:<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:FA=\sqrt{\frac{3}{2}\:}\frac{\sqrt{{({{\uplambda\:}}_{1}-&lt;{\uplambda\:}&gt;)}^{2}+{({{\uplambda\:}}_{2}-&lt;{\uplambda\:}&gt;)}^{2}+{({{\uplambda\:}}_{3}-&lt;{\uplambda\:}&gt;)}^{2}\:}}{\sqrt{{{\uplambda\:}}_{1}^{2}+{{\uplambda\:}}_{2}^{2}+{{\uplambda\:}}_{3}^{2}}}\in\:\left[01\right]$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="12883_2024_3904_Article_Equa.gif"/></alternatives></disp-formula><disp-formula id="Equb"><alternatives><tex-math id="M2">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:&lt;{\uplambda\:}&gt;=\frac{{{\uplambda\:}}_{1}+\:{{\uplambda\:}}_{2}+{{\uplambda\:}}_{3}}{3}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="12883_2024_3904_Article_Equb.gif"/></alternatives></disp-formula></p><p id="Par16">In the mentioned formula &lt; λ &gt; was defined as mean diffusivity (MD). In addition, Axial diffusivity (AxD) was equal to λ<sub>1</sub> (largest eigenvalue). Radial diffusivity (RD) values were defined through the following formula:<disp-formula id="Equc"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:RD=\frac{{{\uplambda\:}}_{2}+{{\uplambda\:}}_{3}}{2}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="12883_2024_3904_Article_Equc.gif"/></alternatives></disp-formula></p></sec><sec id="Sec8"><title>White matter tract atlas and ROI summary measures</title><p id="Par17">The FA images of the Johns Hopkins University (JHU) DTI atlas (ICBM-DTI-81) were used as the template to register the FA image of each subject [<xref ref-type="bibr" rid="CR36">36</xref>]. In this regard, the following regions of interest (ROIs) were evaluated: Genu of the corpus callosum, Posterior thalamic radiation, Body of corpus callosum, Sagittal stratum, Splenium of the corpus callosum, External capsule, Cingulum (cingulate gyrus), Corticospinal tract, Cingulum (hippocampus), Cerebral peduncle, Fornix (crus)/Stria terminalis, Anterior limb of internal capsule, Superior longitudinal fasciculus, Posterior limb of internal capsule, Superior fronto-occipital fasciculus, Retrolenticular part of internal capsule, Inferior fronto-occipital fasciculus, Anterior corona radiata, Uncinate fasciculus, Superior corona radiata, Tapetum, and Posterior corona radiata. Beside JHU labels, additional ROIs including the entire corpus callosum, bilateral genu, body, and splenium of the corpus callosum were assessed.</p></sec><sec id="Sec9"><title>TBSS tract atlas</title><p id="Par18">The implementation of tract-based spatial statistics (TBSS) [<xref ref-type="bibr" rid="CR37">37</xref>], was carried out using the FSL software package (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fmrib.ox.ac.uk/fsl/">http://www.fmrib.ox.ac.uk/fsl/</ext-link>), in accordance with the protocols delineated by the ENIGMA-DTI group. The corrected fractional anisotropy (FA) maps for each subject were first linearly registered and then elastically registered to the ENIGMA-DTI template in ICBM space. The resulting 3D deformation fields were applied to the three diffusivity maps. Subsequently, the spatially normalized data for FA, mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AxD) from all subjects were projected onto the skeletonized ENIGMA-DTI template. The tissue-specific, smoothing-compensated method (T-SPOON) was employed to enhance tissue specificity and mitigate confounding factors arising from morphometric variations that remain inadequately addressed by elastic registration [<xref ref-type="bibr" rid="CR38">38</xref>].</p></sec><sec id="Sec10"><title>Statistical analysis</title><p id="Par19">A one-way ANOVA and Chi-square tests were applied to the demographic data of the participants. Data normality was assessed using the Kolmogorov-Smirnov and Shapiro-Wilk tests. To assess the difference between the baseline values of GAP-43 in five groups, Kruskal-Wallis H was performed. To compare the value of the GAP-43 between three groups of normal, early and late MCI groups with 2 years and 4 years of follow-up, data were log-transformed and analyzed through repeated measure ANOVA. In addition, the rate of GAP-43 alternation after one year was visualized in a box plot. In evaluating the changes in the DTI values, the Friedman test was implemented with a two-year follow-up. Finally, to assess whether there is a correlation between the GAP-43 and DTI values, the Spearman test was conducted. In all of the above tests, the p-value below 0.05 was indicated as significant.</p></sec></sec><sec id="Sec11"><title>Results</title><p id="Par20">Participants age range from 55 to 91 (mean: 73.08 years old). Data were allocated into five groups normal, early and late MCI, and AD considering the ADNI classification, which was based on the Mini-Mental State Examination (MMSE) score and the physician report on the state of the disease which was based on the clinical presentation, imaging findings and cognitive tests, including Clinical Dementia Rating Scale (Table <xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par21">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Demographic information of participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Normal (<italic toggle="yes">n</italic> = 48)</th><th align="left" colspan="1" rowspan="1">Early MCI (<italic toggle="yes">n</italic> = 23)</th><th align="left" colspan="1" rowspan="1">MCI (<italic toggle="yes">n</italic> = 24)</th><th align="left" colspan="1" rowspan="1">Late MCI (<italic toggle="yes">n</italic> = 19)</th><th align="left" colspan="1" rowspan="1">AD (<italic toggle="yes">n</italic> = 19)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (Year)</td><td align="left" colspan="1" rowspan="1">73.29 ± 5.971</td><td align="left" colspan="1" rowspan="1">72.7 ± 7.654</td><td align="left" colspan="1" rowspan="1">72.58 ± 9.179</td><td align="left" colspan="1" rowspan="1">73.79 ± 6.372</td><td align="left" colspan="1" rowspan="1">72.63 ± 9.47</td><td char="." align="char" colspan="1" rowspan="1">0.975</td></tr><tr><td align="left" colspan="1" rowspan="1">Gender (Male/ Female)</td><td align="left" colspan="1" rowspan="1">18/30</td><td align="left" colspan="1" rowspan="1">12/11</td><td align="left" colspan="1" rowspan="1">18/6</td><td align="left" colspan="1" rowspan="1">14/5</td><td align="left" colspan="1" rowspan="1">8/11</td><td char="." align="char" colspan="1" rowspan="1">0.008</td></tr><tr><td align="left" colspan="1" rowspan="1">Education</td><td align="left" colspan="1" rowspan="1">16.92 ± 2.386</td><td align="left" colspan="1" rowspan="1">16 ± 3.09</td><td align="left" colspan="1" rowspan="1">15.68 ± 2.81</td><td align="left" colspan="1" rowspan="1">16.83 ± 2.531</td><td align="left" colspan="1" rowspan="1">15.37 ± 2.81</td><td char="." align="char" colspan="1" rowspan="1">0.137</td></tr><tr><td align="left" colspan="1" rowspan="1">GAP-43 Baseline</td><td align="left" colspan="1" rowspan="1">4698.56 ± 2407.34</td><td align="left" colspan="1" rowspan="1">5259.73 ± 2463.93</td><td align="left" colspan="1" rowspan="1">7074 ± 3756.56</td><td align="left" colspan="1" rowspan="1">4927.74 ± 3907.52</td><td align="left" colspan="1" rowspan="1">6791.98 ± 4643.93</td><td char="." align="char" colspan="1" rowspan="1">0.022</td></tr></tbody></table></table-wrap>
</p><p id="Par22">First, the amount of GAP-43 in CSF was evaluated in normal, early, and late MCI, and AD participants. The changes in the value of GAP-43 in each group were investigated in two and four-year follow-ups. Subsequently, the DTI values in all parameters of all brain areas were evaluated between normal, early, and late MCI subgroups in three consequence visits over two years. Eventually, the correlation between the affected areas in the brain and the GAP-43 levels was assessed.</p><sec id="Sec12"><title>GAP-43</title><p id="Par23">Using the Kruskal-Wallis H test, the GAP-43 level in CSF significantly increases as the disease progresses (P-value = 0.039). By performing a longitudinal analysis, it could be perceived that GAP-43 changes are mainly revealed after four years. Although both groups of normal and early MCI experience significant changes with a p-value less than 0.05, the rate of the changes is higher compared to normal individuals according to mean differences. The GAP-43 measurements in the late MCI with the four-year follow-up were excluded due to the extremely limited sample size (Table <xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par24">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Repeated measure ANOVA test results were conducted on normal, early and late MCI groups with two and four years follow-ups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="7" rowspan="1">Pairwise Comparisons</th></tr><tr><th align="left" rowspan="2" colspan="1">Measure: GAP-43</th><th align="left" rowspan="2" colspan="1">Group number</th><th align="left" rowspan="2" colspan="1">Mean Difference</th><th align="left" rowspan="2" colspan="1">Standard error</th><th align="left" rowspan="2" colspan="1">Significant</th><th align="left" colspan="2" rowspan="1">95% Confidence Interval for Difference</th></tr><tr><th align="left" colspan="1" rowspan="1">Lower Bound</th><th align="left" colspan="1" rowspan="1">Upper Bound</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">2 years follow-up</td><td align="left" colspan="1" rowspan="1">Normal group (19)</td><td align="left" colspan="1" rowspan="1">-146.463</td><td align="left" colspan="1" rowspan="1">106.654</td><td align="left" colspan="1" rowspan="1">0.187</td><td align="left" colspan="1" rowspan="1">-370.535</td><td align="left" colspan="1" rowspan="1">77.609</td></tr><tr><td align="left" colspan="1" rowspan="1">Early MCI (6)</td><td align="left" colspan="1" rowspan="1">-264.292</td><td align="left" colspan="1" rowspan="1">336.975</td><td align="left" colspan="1" rowspan="1">0.468</td><td align="left" colspan="1" rowspan="1">-1130.514</td><td align="left" colspan="1" rowspan="1">601.931</td></tr><tr><td align="left" colspan="1" rowspan="1">Late MCI (12)</td><td align="left" colspan="1" rowspan="1">-302.767</td><td align="left" colspan="1" rowspan="1">199.179</td><td align="left" colspan="1" rowspan="1">0.157</td><td align="left" colspan="1" rowspan="1">-741.157</td><td align="left" colspan="1" rowspan="1">135.624</td></tr><tr><td align="left" rowspan="2" colspan="1">4 years follow-up</td><td align="left" colspan="1" rowspan="1">Normal group (9)</td><td align="left" colspan="1" rowspan="1">-152.558</td><td align="left" colspan="1" rowspan="1">59.861</td><td align="left" colspan="1" rowspan="1">0.034*</td><td align="left" colspan="1" rowspan="1">-290.598</td><td align="left" colspan="1" rowspan="1">-14.519</td></tr><tr><td align="left" colspan="1" rowspan="1">Early MCI (14)</td><td align="left" colspan="1" rowspan="1">-405.920</td><td align="left" colspan="1" rowspan="1">135.142</td><td align="left" colspan="1" rowspan="1">0.010*</td><td align="left" colspan="1" rowspan="1">-697.875</td><td align="left" colspan="1" rowspan="1">-113.964</td></tr></tbody></table><table-wrap-foot><p>*significance with p-value &lt; 0.05</p></table-wrap-foot></table-wrap>
</p><p id="Par25">The increase in the level of CSF GAP-43 can be defined by taking a glimpse of each group’s GAP-43 level changes per year. As is illustrated in Fig. <xref rid="Fig2" ref-type="fig">2</xref>, normal participants experienced a slight alternation in the GAP-43 value, whereas the early MCI group experienced a high rate of fluctuation even up to approximately 1200 pg/mL. The fluctuation value becomes more remarkable in the late MCI group with around 400 pg/mL compared to 200 pg/mL in the normal group (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).</p><p id="Par26">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>GAP-43 value changes per year in normal, early and late MCI. Although the values were not significant between groups, it indicates a rise in the mean GAP-43 value in one year if the disease stage progressed</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e809" position="float" orientation="portrait" xlink:href="12883_2024_3904_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec13"><title>DTI measurement</title><p id="Par27">In this section, a comparison was performed between different brain structural pathways of normal, early, and late MCI participants detected by DTI with two-year follow-ups. Since our data contains right-handed participants, we implement our analysis on the left hemisphere of the individuals.</p><p id="Par28">By performing Friedman analyses considering two-year follow-ups in three visits, the following results were obtained. In the early MCI group, a significant change was observed in the cerebral peduncle (<italic toggle="yes">p</italic> = 0.022) and posterior limb of the internal capsule (PLIC) (<italic toggle="yes">p</italic> = 0.009), in the AxD and FA values, respectively. Unlike FA, for the AxD and MD parameters of DTI, the Retrolenticular part of the internal capsule (RPIC) revealed significant change among late MCI participants (<italic toggle="yes">p</italic> = 0.001 and <italic toggle="yes">p</italic> = 0.011). Posterior thalamic radiation revealed significant changes in the normal, early and late MCI group. Moreover, the cingulum cortex depicted significant changes in late MCI compared to normal participants in the FA parameter (<italic toggle="yes">p</italic> = 0.004), nevertheless, in the RD parameter there is a significant change in both normal and late MCI groups (<italic toggle="yes">p</italic> = 0.013 and <italic toggle="yes">p</italic> = 0.019). The significant values of the cerebellar peduncle, Genu of the corpus callosum, and Medial lemniscus are hypothesized to be the consequence of normal aging rather than MCI state. Fornix (cres)/Stria terminalis is another important pathway that is damaged with a remarkable value among MCI participants (FA: early MCI <italic toggle="yes">p</italic> = 0.022, late MCI <italic toggle="yes">p</italic> = 0.002; MD: early MCI: <italic toggle="yes">p</italic> = 0.016). AxD, MD, and RD parameters in the late MCI group specified significant changes in the sagittal stratum (<italic toggle="yes">p</italic> = 0.005, <italic toggle="yes">p</italic> = 0.005, and <italic toggle="yes">p</italic> = 0.007), and Superior fronto-occipital fasciculus (<italic toggle="yes">p</italic> = 0.003, <italic toggle="yes">p</italic> = 0.001, and <italic toggle="yes">p</italic> = 0.001). The cingulum (hippocampus) tract is highlighted for the early MCI signal alternation in AxD and MD (<italic toggle="yes">p</italic> = 0.033 and <italic toggle="yes">p</italic> = 0.032). The AxD anterior and Superior corona radiata neural tract has remarkable changes in the late MCI stage (<italic toggle="yes">p</italic> = 0.002 and <italic toggle="yes">p</italic> = 0.004), in contrast to the Posterior corona radiata. The FA value of the Inferior fronto-occipital fasciculus is not suggested to be involved in the MCI brain changes, since the value is too close to the p-value threshold (<italic toggle="yes">p</italic> = 0.047). Eventually, the changes in DTI values started from the posterior part of the brain (Posterior corona radiata) and continued to the anterior part of the brain (Anterior corona radiata) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). More information regarding the p-values is available in the supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>.</p><p id="Par29">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Statistical maps depicted AxD, FA, MD, and RD values of brain tracts which changes in two years in three groups of normal, early MCI, and late MCI</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e897" position="float" orientation="portrait" xlink:href="12883_2024_3904_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec14"><title>GAP-43 and DTI</title><p id="Par30">Spearman correlation analyses were performed to investigate possible relationships between GAP-43 and DTI values (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). In this analysis, the participants were divided into five groups, normal (<italic toggle="yes">N</italic> = 48), early MCI (<italic toggle="yes">N</italic> = 23), MCI (<italic toggle="yes">N</italic> = 19), late MCI (<italic toggle="yes">N</italic> = 24), and AD (<italic toggle="yes">N</italic> = 19). The DTI tracts for this section were selected based on the tracts with significant changes during MCI.</p><p id="Par31">If we take a glimpse of normal group results, it can be concluded that Cingulum (hippocampus) has a significant negative correlation with GAP-43 in two AxD and MD parameters in the normal group (<italic toggle="yes">r</italic>=-0.331, <italic toggle="yes">p</italic> = 0.021), whereas this tract has a positive correlation in the late MCI (<italic toggle="yes">r</italic> = 0.476, <italic toggle="yes">p</italic> = 0.019) and AD groups (<italic toggle="yes">r</italic> = 0.468, <italic toggle="yes">p</italic> = 0.043). Moreover, the GAP-43 value was significantly correlated with anterior corona radiate in early (MD: <italic toggle="yes">r</italic>=-0.471, <italic toggle="yes">p</italic> = 0.023; RD: <italic toggle="yes">r</italic>=-0.421, <italic toggle="yes">p</italic> = 0.046). On the contrary, among early MCI and MCI groups in AxD value of superior corona radiate (<italic toggle="yes">r</italic>=-0.562, <italic toggle="yes">p</italic> = 0.005 and <italic toggle="yes">r</italic>=-0.484, <italic toggle="yes">p</italic> = 0.036) and AxD (<italic toggle="yes">r</italic>=-0.515, <italic toggle="yes">p</italic> = 0.012; <italic toggle="yes">r</italic> = 0.034, <italic toggle="yes">p</italic> = 0.034), MD (<italic toggle="yes">r</italic>=-0.521, <italic toggle="yes">p</italic> = 0.011; <italic toggle="yes">r</italic>=-0.518, <italic toggle="yes">p</italic> = 0.023), and RD (<italic toggle="yes">r</italic>=-0.520, <italic toggle="yes">p</italic> = 0.011; <italic toggle="yes">p</italic> = 0.030, <italic toggle="yes">r</italic>=-0.498) values of superior fronto-occipital fasciculus, a significant negative correlations with GAP-43 were detected. Eventually, in the early and late MCI group by considering the fornix (cres)/Stria terminalis pathway, there is a significant correlation between GAP-43 and DTI in MD parameter (<italic toggle="yes">r</italic>=-0.478, <italic toggle="yes">p</italic> = 0.021; <italic toggle="yes">r</italic>=-0.425, <italic toggle="yes">p</italic> = 0.038). Based on the results it could be concluded that the GAP-43 value highly correlated with the DTI parameters in the early MCI groups (Suppl Table <xref rid="MOESM1" ref-type="media">2</xref>).</p><p id="Par32">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>GAP-43 correlation with DTI values in five groups of normal, early MCI, MCI, late MCI, and AD</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1030" position="float" orientation="portrait" xlink:href="12883_2024_3904_Fig4_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec15"><title>Discussion</title><p id="Par33">The current study performed a longitude analysis on the level of CSF GAP-43 over two and four years of follow-ups, in which the level of GAP-43 revealed a significant increase after four years. Moreover, changes in the DTI values in different brain areas were assessed after two years of follow-up. Finally, an analysis to reveal the correlation between the GAP-43 and the areas of the brain with high changes in DTI values in the disease group was performed.</p><p id="Par34">In the Zhu et al. study, the project initiated with a hypothesis mentioning an increase in CSF GAP-43 levels in AD and MCI subjects. The results acknowledge the fact that the GAP-43 level had a direct correlation with the AD stage determined by the MMSE score. Furthermore, GAP-43 was specified as a potential biomarker for AD follow-up since MCI to AD progression became predictable by tracking the level of CSF GAP-43 [<xref ref-type="bibr" rid="CR39">39</xref>]. Accordingly, the result of our study depicted an enhancement in the GAP-43 value in the different stages of AD, which became significant after four years of follow-ups. Another study with a huge sample size of 787 participants enrolled from the ADNI database implemented a regression model to link CSF GAP-43 to AD progression and other biomarkers. The results illustrated a correlation between CSF GAP-43 and AD stage as well as tau level (<italic toggle="yes">r</italic> = 0.768, <italic toggle="yes">P</italic> &lt; 0.001) and neuroimaging hallmarks such as the volume of the medial temporal lobe and hippocampus [<xref ref-type="bibr" rid="CR40">40</xref>]. In this regard, the current study demonstrated a correlation between CSF GAP-43 and DTI parameters in AD patients and revealed a significant correlation between GAP-43 value and DTI parameters in the early MCI. Just a short time before the results of Qiang et al. study became online; Öhrfelt et al. published a similar article with the same sample size of 787 participants from the ADNI database searching for the correlation between GAP-43 and Amyloid-beta (Aβ) level. The study result reported a higher risk of AD progression in participants with positive Aβ and a high amount of CSF GAP-43, represented by a hazard ratio of 8.56. Meanwhile, the study reported a correlation between GAP-43 and Aβ measured by positron emission tomography (PET) scan [<xref ref-type="bibr" rid="CR41">41</xref>]. Likewise, it could be mentioned in our study that the mean level of GAP-43 was higher in late MCI in comparison to the normal and early MCI groups. Besides, our result related to GAP-43 was justified by the Zhang et al. study. Similar to our study, Zhang et al. mentioned the potential role of GAP-43 in the prediction of dementia onset in follow-ups over a period of 2 or 4 years [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par35">It is worth mentioning the result of the Nabizadeh et al. study in which the correlation of the neurofilament light (Nfl) was calculated in different brain white matter tracks in AD patients from the ADNI database. The result revealed a negative correlation of Nfl with FA value in the fronto-occipital fasciculus, uncinate fasciculus, fornix, corpus callosum, corona radiata, and internal capsule, whereas there was a positive association between the sagittal stratum, hippocampal cingulum, cingulum, and thalamic radiation in AxD, MD, and RD values of DTI [<xref ref-type="bibr" rid="CR27">27</xref>]. In our study, the AxD value of superior corona radiate and RD value of superior fronto-occipital fasciculus had a negative correlation with GAP-43 level in the early and mid-MCI participants. In addition, the MD value of Fornix (cres) / Stria terminalis has a negative correlation in early and late MCI, and the FA value of cingulum (hippocampus) has a positive correlation in late MCI. In addition to the correlation of DTI values with Nfl, there is a positive correlation between CSF values of Nfl and GAP-43 (<italic toggle="yes">r</italic> = 0.36, <italic toggle="yes">p</italic> = 0.015) [<xref ref-type="bibr" rid="CR42">42</xref>]. Finally, in Bergamino et al. research, the DTI imaging technique was specified as a potent application in the detection of microstructural changes in AD. The main imaging hallmark to differentiate AD, MCI, and normal participants was reported as the FA value of fornix and corpus callosum [<xref ref-type="bibr" rid="CR43">43</xref>]. Accordingly, based on our results, Superior fronto-occipital fasciculus, Retrolenticular part of the internal capsule, fornix, and FA value of cingulum were potential DTI biomarkers for categorizing normal, MCI, and AD participants with two years follow-ups.</p><p id="Par36">In the Velazquez et al. research analyzing the ADNI data, the hippocampal volume was determined as a biomarker for predicting the progression of MCI to AD [<xref ref-type="bibr" rid="CR44">44</xref>]. For the early stage of AD, Mondragón et al., who worked on the ADNI database, documented the anterior cingulate cortex as the indispensable part involved in this stage [<xref ref-type="bibr" rid="CR45">45</xref>]. Similarly, in our study, the AxD, MD value of the connection of the cingulum to the hippocampus was a biomarker to differentiate the early and late stages of MCI due to its significant changes over two years. Moreover, in a previously published study, the MD value of the hippocampus was significantly higher in the MCI and AD groups [<xref ref-type="bibr" rid="CR46">46</xref>]. Since the MD value is sensitive to necrosis as well as edema and an increase in AxD value could be an indication of higher CSF density [<xref ref-type="bibr" rid="CR47">47</xref>], it could be concluded that the positive correlation of cingulum (hippocampus) MD and AxD value with GAP-43 detected in the late MCI and AD groups were suggested to be due to necrosis and CSF replacement in these areas. Nir et al. study, which performed analysis on 155 ADNI participants, specified the FA parameter of the DTI as the least sensitive in defining the AD stages [<xref ref-type="bibr" rid="CR30">30</xref>]. Conversely, in our study, the FA value of the cingulum could be used as a marker of AD stages since it had a remarkable difference in following up on the early and late stages of AD.</p><p id="Par37">A combination of GAP-43 and DTI measurements could be a diagnostic and monitoring biomarker to differentiate the early stage of MCI from normal participants. Previous studies mentioned different imaging biomarkers for AD severity. For instance, evaluating microstructural changes detected by DTI highlighted a reduction in the fiber number of perforant pathway along with a reduction in FA values of the entorhinal layer II. These results specified the involvement of the entorhinal-hippocampal pathway not only in AD participants but also the preclinical AD [<xref ref-type="bibr" rid="CR48">48</xref>]. Another study applied Quantitative susceptibility mapping (QSM) in the AD group to detect iron accumulation in the tissue as an indicator of AD pathology landmark [<xref ref-type="bibr" rid="CR49">49</xref>]. Blood-brain barrier (BBB) imaging tools are another novel imaging technique to assess the pathology of AD. These techniques including ASL-based measuring BBB water exchange rate and DCE-MRI measuring BBB permeability provide precious data regarding the BBB dysfunction in AD [<xref ref-type="bibr" rid="CR50">50</xref>]. Moreover, the combination of QSM and DP-pCASL to analyze brain iron dynamics as well as BBB function to monitor the AD severity along with AD pathology provides promising biomarkers for AD [<xref ref-type="bibr" rid="CR51">51</xref>].</p><p id="Par38">The main limitation in performing this study was the low number of participants after applying filters for patients who took DTI and lumbar punctures for GAP-43. Express differently, the inclusion criteria of our protocol only included patients who took lumbar puncture for GAP-43 evaluation along with DTI imaging in the same year to minimize the possible bias in finding a correlation between the level of GAP-43 and DTI values.</p></sec><sec id="Sec16"><title>Conclusion</title><p id="Par39">Our results suggest a relationship between the GAP-43 biomarker and white matter integrity in certain tracts in patients with a diagnosis of MCI and AD. In recent studies, CSF GAP-43 was illustrated as a reliable synaptic biomarker to detect MCI progression to AD. The level of GAP-43 highly increased over 4 years in both normal, as a result of aging, and early MCI groups with higher intensity due to disease progression. While for the DTI values only two years of follow-ups revealed remarkable changes between normal and MCI patients. Our findings reflected a correlation between WM changes in multiple brain tracks corresponding to AD with the CSF level of GAP-43.</p></sec><sec id="Sec17" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12883_2024_3904_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher’s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This project was supported by the Tehran University of Medical Sciences, Tehran, Iran, under the supervision of Neurotrack as a student research team.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>A.A. contributed to data clearing, data analysis, writing, and editing. A.G. contributed to the writing of the introduction and result section and editing. E.H. contributed to writing the discussion and method section and editing. N.M. contributed to writing the method section. S.M. contributed to data clearing. N.C.N. and A.Ab. contributed to writing the introduction section. M.S. contributed to reviewing and editing the manuscript. M.M. contributed to supervising and writing the first draft of the manuscript. All authors reviewed the final version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>No funding was received for conducting this study.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data collection and sharing for this project is accessible through the ADNI database (adni.loni.usc.edu).</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethical approval</title><p id="Par46">Ethical approval was waived by the local Ethics Committee of Tehran University of Medical Sciences in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.</p></notes><notes id="FPar2"><title>Consent to participate</title><p id="Par47">Informed consent was obtained from all individual participants included in the study based on the ADNI declaration (adni.loni.usc.edu).</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par44">Not applicable.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par45">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>D</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>L</given-names></name></person-group><article-title>A comprehensive review of Alzheimer’s association with related proteins: pathological role and therapeutic significance</article-title><source>Curr Neuropharmacol</source><year>2020</year><volume>18</volume><issue>8</issue><fpage>674</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.2174/1570159X18666200203101828</pub-id><pub-id pub-id-type="pmid">32172687</pub-id><pub-id pub-id-type="pmcid">PMC7536827</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Kumar D, Sharma A, Sharma L. A comprehensive review of Alzheimer’s association with related proteins: pathological role and therapeutic significance. Curr Neuropharmacol. 2020;18(8):674–95.<pub-id pub-id-type="pmid">32172687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1570159X18666200203101828</pub-id><pub-id pub-id-type="pmcid">PMC7536827</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aye</surname><given-names>S</given-names></name><name name-style="western"><surname>Jönsson</surname><given-names>L</given-names></name><name name-style="western"><surname>Gustavsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Tate</surname><given-names>A</given-names></name><name name-style="western"><surname>SG</surname><given-names>P</given-names></name><name name-style="western"><surname>Eriksdotter</surname><given-names>M</given-names></name></person-group><article-title>Effect of mortality in cost-effectiveness modeling of disease-modifying treatment for Alzheimer’s disease</article-title><source>Alzheimer’s Dementia: Diagnosis Assess Disease Monit</source><year>2023</year><volume>15</volume><issue>1</issue><fpage>e12422</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12422</pub-id><pub-id pub-id-type="pmcid">PMC10053186</pub-id><pub-id pub-id-type="pmid">37009338</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Aye S, Jönsson L, Gustavsson A, Tate A, P SG, Eriksdotter M. Effect of mortality in cost-effectiveness modeling of disease-modifying treatment for Alzheimer’s disease. Alzheimer’s Dementia: Diagnosis Assess Disease Monit. 2023;15(1):e12422.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12422</pub-id><pub-id pub-id-type="pmcid">PMC10053186</pub-id><pub-id pub-id-type="pmid">37009338</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah-Abadi</surname><given-names>ME</given-names></name><name name-style="western"><surname>Ariaei</surname><given-names>A</given-names></name><name name-style="western"><surname>Moradi</surname><given-names>F</given-names></name><name name-style="western"><surname>Rustamzadeh</surname><given-names>A</given-names></name><name name-style="western"><surname>Tanha</surname><given-names>RR</given-names></name><name name-style="western"><surname>Sadigh</surname><given-names>N</given-names></name><etal/></person-group><article-title>In Silico Interactions of Natural and Synthetic compounds with Key proteins involved in Alzheimer’s Disease: prospects for Designing new therapeutics compound</article-title><source>Neurotox Res</source><year>2023</year><volume>41</volume><issue>5</issue><fpage>408</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s12640-023-00648-1</pub-id><pub-id pub-id-type="pmid">37086338</pub-id><pub-id pub-id-type="pmcid">PMC10122091</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Shah-Abadi ME, Ariaei A, Moradi F, Rustamzadeh A, Tanha RR, Sadigh N, et al. In Silico Interactions of Natural and Synthetic compounds with Key proteins involved in Alzheimer’s Disease: prospects for Designing new therapeutics compound. Neurotox Res. 2023;41(5):408–30.<pub-id pub-id-type="pmid">37086338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12640-023-00648-1</pub-id><pub-id pub-id-type="pmcid">PMC10122091</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukhopadhyay</surname><given-names>S</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>D</given-names></name></person-group><article-title>A primer on the evolution of aducanumab: the first antibody approved for treatment of Alzheimer’s disease</article-title><source>J Alzheimers Dis</source><year>2021</year><volume>83</volume><issue>4</issue><fpage>1537</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.3233/JAD-215065</pub-id><pub-id pub-id-type="pmid">34366359</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Mukhopadhyay S, Banerjee D. A primer on the evolution of aducanumab: the first antibody approved for treatment of Alzheimer’s disease. J Alzheimers Dis. 2021;83(4):1537–52.<pub-id pub-id-type="pmid">34366359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-215065</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Ariaei A, Ramezani F. The promising impact of Bemcentinib and Repotrectinib on sleep impairment in Alzheimer’s disease. J Biomol Struct Dyn. 2023:1–17.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2023.2276876</pub-id><pub-id pub-id-type="pmid">37909502</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rustamzadeh</surname><given-names>A</given-names></name><name name-style="western"><surname>Tafakhori</surname><given-names>A</given-names></name><name name-style="western"><surname>Ariaei</surname><given-names>A</given-names></name><name name-style="western"><surname>Heydari</surname><given-names>M</given-names></name><name name-style="western"><surname>Shah-Abadi</surname><given-names>ME</given-names></name><name name-style="western"><surname>Seif</surname><given-names>F</given-names></name></person-group><article-title>Targeting Caspases 3/6 and cathepsins L/B May decrease Laminopathy-Induced apoptosis in Alzheimer’s Disease</article-title><source>J Alzheimers Dis</source><year>2024</year><volume>101</volume><issue>1</issue><fpage>211</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.3233/JAD-240413</pub-id><pub-id pub-id-type="pmid">39121120</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Rustamzadeh A, Tafakhori A, Ariaei A, Heydari M, Shah-Abadi ME, Seif F. Targeting Caspases 3/6 and cathepsins L/B May decrease Laminopathy-Induced apoptosis in Alzheimer’s Disease. J Alzheimers Dis. 2024;101(1):211–21.<pub-id pub-id-type="pmid">39121120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-240413</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Usefi F, Rustamzadeh A, Ghobadi Z, Sadigh N, Mohebi N, Ariaei A et al. Rosuvastatin attenuates total-tau serum levels and increases expression of miR-124-3p in dyslipidemic Alzheimer’s patients: a historic cohort study. Metab Brain Dis. 2024:1–11.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11011-024-01371-2</pub-id><pub-id pub-id-type="pmid">38896205</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>HG</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J-H</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>ES</given-names></name><name name-style="western"><surname>Park</surname><given-names>HY</given-names></name><name name-style="western"><surname>Min</surname><given-names>K-W</given-names></name><etal/></person-group><article-title>Associations between Proton pump inhibitors and Alzheimer’s disease: a nested case–control study using a Korean nationwide health screening cohort</article-title><source>Alzheimers Res Ther</source><year>2022</year><volume>14</volume><issue>1</issue><fpage>91</fpage><pub-id pub-id-type="doi">10.1186/s13195-022-01032-5</pub-id><pub-id pub-id-type="pmid">35773740</pub-id><pub-id pub-id-type="pmcid">PMC9248149</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Choi HG, Kim J-H, Kim JH, Kim ES, Park HY, Min K-W, et al. Associations between Proton pump inhibitors and Alzheimer’s disease: a nested case–control study using a Korean nationwide health screening cohort. Alzheimers Res Ther. 2022;14(1):91.<pub-id pub-id-type="pmid">35773740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-022-01032-5</pub-id><pub-id pub-id-type="pmcid">PMC9248149</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brandes Lourenço</surname><given-names>R</given-names></name><name name-style="western"><surname>Machado de Campos</surname><given-names>B</given-names></name><name name-style="western"><surname>Rizzi</surname><given-names>L</given-names></name><name name-style="western"><surname>Sakzenian de Souza</surname><given-names>M</given-names></name><name name-style="western"><surname>Forlenza</surname><given-names>OV</given-names></name><name name-style="western"><surname>Giroud Joaquim</surname><given-names>H</given-names></name><etal/></person-group><article-title>Functional connectome analysis in mild cognitive impairment: comparing Alzheimer’s Disease Continuum and suspected Non-alzheimer Pathology</article-title><source>Brain Connect</source><year>2022</year><volume>12</volume><issue>9</issue><fpage>774</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1089/brain.2021.0154</pub-id><pub-id pub-id-type="pmid">35412854</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Brandes Lourenço R, Machado de Campos B, Rizzi L, Sakzenian de Souza M, Forlenza OV, Giroud Joaquim H, et al. Functional connectome analysis in mild cognitive impairment: comparing Alzheimer’s Disease Continuum and suspected Non-alzheimer Pathology. Brain Connect. 2022;12(9):774–83.<pub-id pub-id-type="pmid">35412854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/brain.2021.0154</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Lu Y, Initiative ADN. Cerebrospinal fluid growth-associated protein 43 levels in patients with progressive and stable mild cognitive impairment. Aging Clin Exp Res. 2022:1–8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40520-022-02202-z</pub-id><pub-id pub-id-type="pmid">35988117</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moscoso</surname><given-names>A</given-names></name><name name-style="western"><surname>Silva-Rodríguez</surname><given-names>J</given-names></name><name name-style="western"><surname>Aldrey</surname><given-names>JM</given-names></name><name name-style="western"><surname>Cortés</surname><given-names>J</given-names></name><name name-style="western"><surname>Fernández-Ferreiro</surname><given-names>A</given-names></name><name name-style="western"><surname>Gómez-Lado</surname><given-names>N</given-names></name><etal/></person-group><article-title>Prediction of Alzheimer’s disease dementia with MRI beyond the short-term: implications for the design of predictive models</article-title><source>NeuroImage: Clin</source><year>2019</year><volume>23</volume><fpage>101837</fpage><pub-id pub-id-type="doi">10.1016/j.nicl.2019.101837</pub-id><pub-id pub-id-type="pmid">31078938</pub-id><pub-id pub-id-type="pmcid">PMC6515129</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Moscoso A, Silva-Rodríguez J, Aldrey JM, Cortés J, Fernández-Ferreiro A, Gómez-Lado N, et al. Prediction of Alzheimer’s disease dementia with MRI beyond the short-term: implications for the design of predictive models. NeuroImage: Clin. 2019;23:101837.<pub-id pub-id-type="pmid">31078938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2019.101837</pub-id><pub-id pub-id-type="pmcid">PMC6515129</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Mohammadi H, Ariaei A, Ghobadi Z, Gorgich EAC, Rustamzadeh A. Which neuroimaging and fluid biomarkers method is better in theranostic of Alzheimer’s disease? An umbrella review. IBRO Neurosci Rep. 2024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ibneur.2024.02.007</pub-id><pub-id pub-id-type="pmcid">PMC10940808</pub-id><pub-id pub-id-type="pmid">38497046</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Peng</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group><article-title>Acrolein, an endogenous aldehyde induces synaptic dysfunction in vitro and in vivo: involvement of RhoA/ROCK2 pathway</article-title><source>Aging Cell</source><year>2022</year><volume>21</volume><issue>4</issue><fpage>e13587</fpage><pub-id pub-id-type="doi">10.1111/acel.13587</pub-id><pub-id pub-id-type="pmid">35315217</pub-id><pub-id pub-id-type="pmcid">PMC9009232</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Zhu Z, Lu J, Wang S, Peng W, Yang Y, Chen C, et al. Acrolein, an endogenous aldehyde induces synaptic dysfunction in vitro and in vivo: involvement of RhoA/ROCK2 pathway. Aging Cell. 2022;21(4):e13587.<pub-id pub-id-type="pmid">35315217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.13587</pub-id><pub-id pub-id-type="pmcid">PMC9009232</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sandelius</surname><given-names>Å</given-names></name><name name-style="western"><surname>Portelius</surname><given-names>E</given-names></name><name name-style="western"><surname>Källén</surname><given-names>Å</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name><name name-style="western"><surname>Rot</surname><given-names>U</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>B</given-names></name><etal/></person-group><article-title>Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology</article-title><source>Alzheimer’s Dement</source><year>2019</year><volume>15</volume><issue>1</issue><fpage>55</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2018.08.006</pub-id><pub-id pub-id-type="pmid">30321501</pub-id><pub-id pub-id-type="pmcid">PMC6333489</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Sandelius Å, Portelius E, Källén Å, Zetterberg H, Rot U, Olsson B, et al. Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology. Alzheimer’s Dement. 2019;15(1):55–64.<pub-id pub-id-type="pmid">30321501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.08.006</pub-id><pub-id pub-id-type="pmcid">PMC6333489</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Patil AA. Characterization of GAP43-Gfp Fusion protein in PC12 and NIH3T3 stable transfectant cells. Texas A&amp;M University-Kingsville; 2021.</mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Maroto I, Costas-Insua C, Berthoux C, Moreno E, Ruiz-Calvo A, Montero-Fernández C et al. Control of a hippocampal recurrent Excitatory Circuit by Cannabinoid receptor-interacting protein Gap43. 2022.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-38026-2</pub-id><pub-id pub-id-type="pmcid">PMC10121561</pub-id><pub-id pub-id-type="pmid">37085487</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Q-L</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y-Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A-J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W-D</given-names></name></person-group><article-title>Formononetin recovered injured nerve functions by enhancing synaptic plasticity in ischemic stroke rats</article-title><source>Biochem Biophys Res Commun</source><year>2020</year><volume>525</volume><issue>1</issue><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.02.015</pub-id><pub-id pub-id-type="pmid">32081422</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Wu Q-L, Cheng Y-Q, Liu A-J, Zhang W-D. Formononetin recovered injured nerve functions by enhancing synaptic plasticity in ischemic stroke rats. Biochem Biophys Res Commun. 2020;525(1):67–72.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2020.02.015</pub-id><pub-id pub-id-type="pmid">32081422</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holahan</surname><given-names>MR</given-names></name></person-group><article-title>A shift from a pivotal to supporting role for the growth-associated protein (GAP-43) in the coordination of axonal structural and functional plasticity</article-title><source>Front Cell Neurosci</source><year>2017</year><volume>11</volume><fpage>266</fpage><pub-id pub-id-type="doi">10.3389/fncel.2017.00266</pub-id><pub-id pub-id-type="pmid">28912688</pub-id><pub-id pub-id-type="pmcid">PMC5583208</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Holahan MR. A shift from a pivotal to supporting role for the growth-associated protein (GAP-43) in the coordination of axonal structural and functional plasticity. Front Cell Neurosci. 2017;11:266.<pub-id pub-id-type="pmid">28912688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2017.00266</pub-id><pub-id pub-id-type="pmcid">PMC5583208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Zamzow DR, Elias V, Acosta VA, Escobedo E, Magnusson KR. Higher levels of protein palmitoylation in the frontal cortex across aging were associated with reference memory and executive function declines. Eneuro. 2019;6(1).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/ENEURO.0310-18.2019</pub-id><pub-id pub-id-type="pmcid">PMC6366935</pub-id><pub-id pub-id-type="pmid">30740518</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramesh</surname><given-names>M</given-names></name><name name-style="western"><surname>Govindaraju</surname><given-names>T</given-names></name></person-group><article-title>Multipronged diagnostic and therapeutic strategies for Alzheimer’s disease</article-title><source>Chem Sci</source><year>2022</year><volume>13</volume><issue>46</issue><fpage>13657</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1039/D2SC03932J</pub-id><pub-id pub-id-type="pmid">36544728</pub-id><pub-id pub-id-type="pmcid">PMC9710308</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Ramesh M, Govindaraju T. Multipronged diagnostic and therapeutic strategies for Alzheimer’s disease. Chem Sci. 2022;13(46):13657–89.<pub-id pub-id-type="pmid">36544728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d2sc03932j</pub-id><pub-id pub-id-type="pmcid">PMC9710308</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersson</surname><given-names>A</given-names></name><name name-style="western"><surname>Remnestål</surname><given-names>J</given-names></name><name name-style="western"><surname>Nellgård</surname><given-names>B</given-names></name><name name-style="western"><surname>Vunk</surname><given-names>H</given-names></name><name name-style="western"><surname>Kotol</surname><given-names>D</given-names></name><name name-style="western"><surname>Edfors</surname><given-names>F</given-names></name><etal/></person-group><article-title>Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer’s disease</article-title><source>Clin Chim Acta</source><year>2019</year><volume>494</volume><fpage>79</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2019.03.243</pub-id><pub-id pub-id-type="pmid">30858094</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Andersson A, Remnestål J, Nellgård B, Vunk H, Kotol D, Edfors F, et al. Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer’s disease. Clin Chim Acta. 2019;494:79–93.<pub-id pub-id-type="pmid">30858094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cca.2019.03.243</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pieri</surname><given-names>V</given-names></name><name name-style="western"><surname>Trovatelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Cadioli</surname><given-names>M</given-names></name><name name-style="western"><surname>Zani</surname><given-names>DD</given-names></name><name name-style="western"><surname>Brizzola</surname><given-names>S</given-names></name><name name-style="western"><surname>Ravasio</surname><given-names>G</given-names></name><etal/></person-group><article-title>In vivo diffusion tensor magnetic resonance tractography of the sheep brain: an atlas of the ovine white matter fiber bundles</article-title><source>Front Veterinary Sci</source><year>2019</year><volume>6</volume><fpage>345</fpage><pub-id pub-id-type="doi">10.3389/fvets.2019.00345</pub-id><pub-id pub-id-type="pmcid">PMC6805705</pub-id><pub-id pub-id-type="pmid">31681805</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Pieri V, Trovatelli M, Cadioli M, Zani DD, Brizzola S, Ravasio G, et al. In vivo diffusion tensor magnetic resonance tractography of the sheep brain: an atlas of the ovine white matter fiber bundles. Front Veterinary Sci. 2019;6:345.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fvets.2019.00345</pub-id><pub-id pub-id-type="pmcid">PMC6805705</pub-id><pub-id pub-id-type="pmid">31681805</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Contarino</surname><given-names>VE</given-names></name><name name-style="western"><surname>Siggillino</surname><given-names>S</given-names></name><name name-style="western"><surname>Arighi</surname><given-names>A</given-names></name><name name-style="western"><surname>Scola</surname><given-names>E</given-names></name><name name-style="western"><surname>Fumagalli</surname><given-names>GG</given-names></name><name name-style="western"><surname>Conte</surname><given-names>G</given-names></name><etal/></person-group><article-title>Association of superficial white matter alterations with cerebrospinal fluid biomarkers and cognitive decline in neurodegenerative dementia</article-title><source>J Alzheimers Dis</source><year>2022</year><volume>85</volume><issue>1</issue><fpage>431</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.3233/JAD-215003</pub-id><pub-id pub-id-type="pmid">34864664</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Contarino VE, Siggillino S, Arighi A, Scola E, Fumagalli GG, Conte G, et al. Association of superficial white matter alterations with cerebrospinal fluid biomarkers and cognitive decline in neurodegenerative dementia. J Alzheimers Dis. 2022;85(1):431–42.<pub-id pub-id-type="pmid">34864664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-215003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebrahimi Shah-abadi</surname><given-names>M</given-names></name><name name-style="western"><surname>Ariaei</surname><given-names>A</given-names></name><name name-style="western"><surname>Mohammadi</surname><given-names>H</given-names></name><name name-style="western"><surname>Shabani</surname><given-names>A</given-names></name><name name-style="western"><surname>Rahmani Tanha</surname><given-names>R</given-names></name><name name-style="western"><surname>Tavakolian Ferdousie</surname><given-names>V</given-names></name><etal/></person-group><article-title>Recent advances and future directions in imaging of Peripheral Nervous System: a comprehensive review for therapeutics Approach</article-title><source>J Adv Med Biomedical Res</source><year>2023</year><volume>31</volume><issue>148</issue><fpage>415</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.30699/jambs.31.148.415</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Ebrahimi Shah-abadi M, Ariaei A, Mohammadi H, Shabani A, Rahmani Tanha R, Tavakolian Ferdousie V, et al. Recent advances and future directions in imaging of Peripheral Nervous System: a comprehensive review for therapeutics Approach. J Adv Med Biomedical Res. 2023;31(148):415–31.</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Miller B, Kim S-J, Mehta HH, Cao K, Kumagai H, Thumaty N et al. Mitochondrial DNA variation in Alzheimer’s disease reveals a unique microprotein called SHMOOSE. Mol Psychiatry. 2022:1–14.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-022-01769-3</pub-id><pub-id pub-id-type="pmcid">PMC10027624</pub-id><pub-id pub-id-type="pmid">36127429</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nabizadeh</surname><given-names>F</given-names></name><name name-style="western"><surname>Pourhamzeh</surname><given-names>M</given-names></name><name name-style="western"><surname>Khani</surname><given-names>S</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>A</given-names></name><name name-style="western"><surname>Ranjbaran</surname><given-names>F</given-names></name><name name-style="western"><surname>Deravi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Plasma phosphorylated-tau181 levels reflect white matter microstructural changes across Alzheimer’s disease progression</article-title><source>Metab Brain Dis</source><year>2022</year><volume>37</volume><issue>3</issue><fpage>761</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1007/s11011-022-00908-7</pub-id><pub-id pub-id-type="pmid">35015198</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Nabizadeh F, Pourhamzeh M, Khani S, Rezaei A, Ranjbaran F, Deravi N, et al. Plasma phosphorylated-tau181 levels reflect white matter microstructural changes across Alzheimer’s disease progression. Metab Brain Dis. 2022;37(3):761–71.<pub-id pub-id-type="pmid">35015198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11011-022-00908-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nabizadeh</surname><given-names>F</given-names></name><name name-style="western"><surname>Balabandian</surname><given-names>M</given-names></name><name name-style="western"><surname>Rostami</surname><given-names>MR</given-names></name><name name-style="western"><surname>Kankam</surname><given-names>SB</given-names></name><name name-style="western"><surname>Ranjbaran</surname><given-names>F</given-names></name><name name-style="western"><surname>Pourhamzeh</surname><given-names>M</given-names></name><etal/></person-group><article-title>Plasma neurofilament light levels correlate with white matter damage prior to Alzheimer’s disease: results from ADNI</article-title><source>Aging Clin Exp Res</source><year>2022</year><volume>34</volume><issue>10</issue><fpage>2363</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1007/s40520-022-02095-y</pub-id><pub-id pub-id-type="pmid">35226303</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Nabizadeh F, Balabandian M, Rostami MR, Kankam SB, Ranjbaran F, Pourhamzeh M, et al. Plasma neurofilament light levels correlate with white matter damage prior to Alzheimer’s disease: results from ADNI. Aging Clin Exp Res. 2022;34(10):2363–72.<pub-id pub-id-type="pmid">35226303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40520-022-02095-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>D</given-names></name><name name-style="western"><surname>Jia</surname><given-names>J</given-names></name><collab>Initiative AsDN</collab></person-group><article-title>The trajectory of cerebrospinal fluid growth-associated protein 43 in the Alzheimer’s disease continuum: a longitudinal study</article-title><source>J Alzheimers Dis</source><year>2022</year><volume>Preprint</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-215456</pub-id><pub-id pub-id-type="pmid">34958042</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Zhang H, Lyu D, Jia J, Initiative AsDN. The trajectory of cerebrospinal fluid growth-associated protein 43 in the Alzheimer’s disease continuum: a longitudinal study. J Alzheimers Dis. 2022;Preprint:1–12.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-215456</pub-id><pub-id pub-id-type="pmid">34958042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGrowder</surname><given-names>DA</given-names></name><name name-style="western"><surname>Miller</surname><given-names>F</given-names></name><name name-style="western"><surname>Vaz</surname><given-names>K</given-names></name><name name-style="western"><surname>Nwokocha</surname><given-names>C</given-names></name><name name-style="western"><surname>Wilson-Clarke</surname><given-names>C</given-names></name><name name-style="western"><surname>Anderson-Cross</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid biomarkers of Alzheimer’s disease: current evidence and future perspectives</article-title><source>Brain Sci</source><year>2021</year><volume>11</volume><issue>2</issue><fpage>215</fpage><pub-id pub-id-type="doi">10.3390/brainsci11020215</pub-id><pub-id pub-id-type="pmid">33578866</pub-id><pub-id pub-id-type="pmcid">PMC7916561</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">McGrowder DA, Miller F, Vaz K, Nwokocha C, Wilson-Clarke C, Anderson-Cross M, et al. Cerebrospinal fluid biomarkers of Alzheimer’s disease: current evidence and future perspectives. Brain Sci. 2021;11(2):215.<pub-id pub-id-type="pmid">33578866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci11020215</pub-id><pub-id pub-id-type="pmcid">PMC7916561</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nir</surname><given-names>TM</given-names></name><name name-style="western"><surname>Jahanshad</surname><given-names>N</given-names></name><name name-style="western"><surname>Villalon-Reina</surname><given-names>JE</given-names></name><name name-style="western"><surname>Toga</surname><given-names>AW</given-names></name><name name-style="western"><surname>Jack</surname><given-names>CR</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Effectiveness of regional DTI measures in distinguishing Alzheimer’s disease, MCI, and normal aging</article-title><source>NeuroImage: Clin</source><year>2013</year><volume>3</volume><fpage>180</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.nicl.2013.07.006</pub-id><pub-id pub-id-type="pmid">24179862</pub-id><pub-id pub-id-type="pmcid">PMC3792746</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Nir TM, Jahanshad N, Villalon-Reina JE, Toga AW, Jack CR, Weiner MW, et al. Effectiveness of regional DTI measures in distinguishing Alzheimer’s disease, MCI, and normal aging. NeuroImage: Clin. 2013;3:180–95.<pub-id pub-id-type="pmid">24179862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2013.07.006</pub-id><pub-id pub-id-type="pmcid">PMC3792746</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iglesias</surname><given-names>JE</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CY</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>PM</given-names></name><name name-style="western"><surname>Tu</surname><given-names>Z</given-names></name></person-group><article-title>Robust brain extraction across datasets and comparison with publicly available methods</article-title><source>IEEE Trans Med Imaging</source><year>2011</year><volume>30</volume><issue>9</issue><fpage>1617</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1109/TMI.2011.2138152</pub-id><pub-id pub-id-type="pmid">21880566</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Iglesias JE, Liu CY, Thompson PM, Tu Z. Robust brain extraction across datasets and comparison with publicly available methods. IEEE Trans Med Imaging. 2011;30(9):1617–34.<pub-id pub-id-type="pmid">21880566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TMI.2011.2138152</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischl</surname><given-names>B</given-names></name><name name-style="western"><surname>van der Kouwe</surname><given-names>A</given-names></name><name name-style="western"><surname>Destrieux</surname><given-names>C</given-names></name><name name-style="western"><surname>Halgren</surname><given-names>E</given-names></name><name name-style="western"><surname>Ségonne</surname><given-names>F</given-names></name><name name-style="western"><surname>Salat</surname><given-names>DH</given-names></name><etal/></person-group><article-title>Automatically parcellating the human cerebral cortex</article-title><source>Cereb Cortex</source><year>2004</year><volume>14</volume><issue>1</issue><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhg087</pub-id><pub-id pub-id-type="pmid">14654453</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Fischl B, van der Kouwe A, Destrieux C, Halgren E, Ségonne F, Salat DH, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004;14(1):11–22.<pub-id pub-id-type="pmid">14654453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhg087</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>SM</given-names></name></person-group><article-title>Fast robust automated brain extraction</article-title><source>Hum Brain Mapp</source><year>2002</year><volume>17</volume><issue>3</issue><fpage>143</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1002/hbm.10062</pub-id><pub-id pub-id-type="pmid">12391568</pub-id><pub-id pub-id-type="pmcid">PMC6871816</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17(3):143–55.<pub-id pub-id-type="pmid">12391568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.10062</pub-id><pub-id pub-id-type="pmcid">PMC6871816</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jenkinson</surname><given-names>M</given-names></name><name name-style="western"><surname>Bannister</surname><given-names>P</given-names></name><name name-style="western"><surname>Brady</surname><given-names>M</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S</given-names></name></person-group><article-title>Improved optimization for the robust and accurate linear registration and motion correction of brain images</article-title><source>NeuroImage</source><year>2002</year><volume>17</volume><issue>2</issue><fpage>825</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1006/nimg.2002.1132</pub-id><pub-id pub-id-type="pmid">12377157</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. NeuroImage. 2002;17(2):825–41.<pub-id pub-id-type="pmid">12377157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1053-8119(02)91132-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leow</surname><given-names>AD</given-names></name><name name-style="western"><surname>Yanovsky</surname><given-names>I</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>MC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>AD</given-names></name><name name-style="western"><surname>Klunder</surname><given-names>AD</given-names></name><name name-style="western"><surname>Lu</surname><given-names>A</given-names></name><etal/></person-group><article-title>Statistical properties of jacobian maps and the realization of unbiased large-deformation nonlinear image registration</article-title><source>IEEE Trans Med Imaging</source><year>2007</year><volume>26</volume><issue>6</issue><fpage>822</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1109/TMI.2007.892646</pub-id><pub-id pub-id-type="pmid">17679333</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Leow AD, Yanovsky I, Chiang MC, Lee AD, Klunder AD, Lu A, et al. Statistical properties of jacobian maps and the realization of unbiased large-deformation nonlinear image registration. IEEE Trans Med Imaging. 2007;26(6):822–32.<pub-id pub-id-type="pmid">17679333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TMI.2007.892646</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mori</surname><given-names>S</given-names></name><name name-style="western"><surname>Oishi</surname><given-names>K</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Akhter</surname><given-names>K</given-names></name><etal/></person-group><article-title>Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template</article-title><source>NeuroImage</source><year>2008</year><volume>40</volume><issue>2</issue><fpage>570</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2007.12.035</pub-id><pub-id pub-id-type="pmid">18255316</pub-id><pub-id pub-id-type="pmcid">PMC2478641</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Mori S, Oishi K, Jiang H, Jiang L, Li X, Akhter K, et al. Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. NeuroImage. 2008;40(2):570–82.<pub-id pub-id-type="pmid">18255316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2007.12.035</pub-id><pub-id pub-id-type="pmcid">PMC2478641</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>SM</given-names></name><name name-style="western"><surname>Jenkinson</surname><given-names>M</given-names></name><name name-style="western"><surname>Johansen-Berg</surname><given-names>H</given-names></name><name name-style="western"><surname>Rueckert</surname><given-names>D</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>TE</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data</article-title><source>NeuroImage</source><year>2006</year><volume>31</volume><issue>4</issue><fpage>1487</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2006.02.024</pub-id><pub-id pub-id-type="pmid">16624579</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. NeuroImage. 2006;31(4):1487–505.<pub-id pub-id-type="pmid">16624579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2006.02.024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JE</given-names></name><name name-style="western"><surname>Chung</surname><given-names>MK</given-names></name><name name-style="western"><surname>Lazar</surname><given-names>M</given-names></name><name name-style="western"><surname>DuBray</surname><given-names>MB</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Bigler</surname><given-names>ED</given-names></name><etal/></person-group><article-title>A study of diffusion tensor imaging by tissue-specific, smoothing-compensated voxel-based analysis</article-title><source>NeuroImage</source><year>2009</year><volume>44</volume><issue>3</issue><fpage>870</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2008.09.041</pub-id><pub-id pub-id-type="pmid">18976713</pub-id><pub-id pub-id-type="pmcid">PMC2657194</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Lee JE, Chung MK, Lazar M, DuBray MB, Kim J, Bigler ED, et al. A study of diffusion tensor imaging by tissue-specific, smoothing-compensated voxel-based analysis. NeuroImage. 2009;44(3):870–83.<pub-id pub-id-type="pmid">18976713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2008.09.041</pub-id><pub-id pub-id-type="pmcid">PMC2657194</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Initiative</surname><given-names>ADN</given-names></name></person-group><article-title>Association of CSF GAP-43 and APOE ε4 with cognition in mild cognitive impairment and Alzheimer’s Disease</article-title><source>Cells</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>13</fpage><pub-id pub-id-type="doi">10.3390/cells12010013</pub-id><pub-id pub-id-type="pmid">36611808</pub-id><pub-id pub-id-type="pmcid">PMC9818551</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Zhu Y, Guo X, Zhu F, Zhang Q, Yang Y, Initiative ADN. Association of CSF GAP-43 and APOE ε4 with cognition in mild cognitive impairment and Alzheimer’s Disease. Cells. 2022;12(1):13.<pub-id pub-id-type="pmid">36611808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells12010013</pub-id><pub-id pub-id-type="pmcid">PMC9818551</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Skudder-Hill</surname><given-names>L</given-names></name><name name-style="western"><surname>Toyota</surname><given-names>T</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W</given-names></name><name name-style="western"><surname>Adachi</surname><given-names>H</given-names></name></person-group><article-title>CSF GAP-43 as a biomarker of synaptic dysfunction is associated with tau pathology in Alzheimer’s disease</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>17392</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-20324-2</pub-id><pub-id pub-id-type="pmid">36253408</pub-id><pub-id pub-id-type="pmcid">PMC9576773</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Qiang Q, Skudder-Hill L, Toyota T, Wei W, Adachi H. CSF GAP-43 as a biomarker of synaptic dysfunction is associated with tau pathology in Alzheimer’s disease. Sci Rep. 2022;12(1):17392.<pub-id pub-id-type="pmid">36253408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-20324-2</pub-id><pub-id pub-id-type="pmcid">PMC9576773</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Öhrfelt</surname><given-names>A</given-names></name><name name-style="western"><surname>Benedet</surname><given-names>AL</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Kvartsberg</surname><given-names>H</given-names></name><name name-style="western"><surname>Vandijck</surname><given-names>M</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Association of CSF GAP-43 with the rate of Cognitive decline and progression to dementia in amyloid-positive individuals</article-title><source>Neurology</source><year>2023</year><volume>100</volume><issue>3</issue><fpage>e275</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000201417</pub-id><pub-id pub-id-type="pmid">36192174</pub-id><pub-id pub-id-type="pmcid">PMC9869758</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Öhrfelt A, Benedet AL, Ashton NJ, Kvartsberg H, Vandijck M, Weiner MW, et al. Association of CSF GAP-43 with the rate of Cognitive decline and progression to dementia in amyloid-positive individuals. Neurology. 2023;100(3):e275–85.<pub-id pub-id-type="pmid">36192174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000201417</pub-id><pub-id pub-id-type="pmcid">PMC9869758</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saloner</surname><given-names>R</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>C</given-names></name><name name-style="western"><surname>Paolillo</surname><given-names>EW</given-names></name><name name-style="western"><surname>Asken</surname><given-names>BM</given-names></name><name name-style="western"><surname>Djukic</surname><given-names>NA</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><etal/></person-group><article-title>Combined effects of synaptic and Axonal Integrity on Longitudinal Gray Matter Atrophy in cognitively unimpaired adults</article-title><source>Neurology</source><year>2022</year><volume>99</volume><issue>20</issue><fpage>e2285</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000201165</pub-id><pub-id pub-id-type="pmid">36041868</pub-id><pub-id pub-id-type="pmcid">PMC9694840</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Saloner R, Fonseca C, Paolillo EW, Asken BM, Djukic NA, Lee S, et al. Combined effects of synaptic and Axonal Integrity on Longitudinal Gray Matter Atrophy in cognitively unimpaired adults. Neurology. 2022;99(20):e2285–93.<pub-id pub-id-type="pmid">36041868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000201165</pub-id><pub-id pub-id-type="pmcid">PMC9694840</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergamino</surname><given-names>M</given-names></name><name name-style="western"><surname>Keeling</surname><given-names>EG</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>RR</given-names></name><name name-style="western"><surname>Stokes</surname><given-names>AM</given-names></name></person-group><article-title>Systematic assessment of the impact of DTI methodology on fractional anisotropy measures in Alzheimer’s disease</article-title><source>Tomography</source><year>2021</year><volume>7</volume><issue>1</issue><fpage>20</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.3390/tomography7010003</pub-id><pub-id pub-id-type="pmid">33681461</pub-id><pub-id pub-id-type="pmcid">PMC7934686</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Bergamino M, Keeling EG, Walsh RR, Stokes AM. Systematic assessment of the impact of DTI methodology on fractional anisotropy measures in Alzheimer’s disease. Tomography. 2021;7(1):20–38.<pub-id pub-id-type="pmid">33681461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/tomography7010003</pub-id><pub-id pub-id-type="pmcid">PMC7934686</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velazquez</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y</given-names></name></person-group><article-title>Multimodal ensemble model for Alzheimer’s disease conversion prediction from early mild cognitive impairment subjects</article-title><source>Comput Biol Med</source><year>2022</year><volume>151</volume><fpage>106201</fpage><pub-id pub-id-type="doi">10.1016/j.compbiomed.2022.106201</pub-id><pub-id pub-id-type="pmid">36370583</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Velazquez M, Lee Y. Multimodal ensemble model for Alzheimer’s disease conversion prediction from early mild cognitive impairment subjects. Comput Biol Med. 2022;151:106201.<pub-id pub-id-type="pmid">36370583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiomed.2022.106201</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mondragón</surname><given-names>JD</given-names></name><name name-style="western"><surname>Maurits</surname><given-names>NM</given-names></name><name name-style="western"><surname>De Deyn</surname><given-names>PP</given-names></name><name name-style="western"><surname>Initiative</surname><given-names>ADN</given-names></name></person-group><article-title>Functional connectivity differences in Alzheimer’s disease and amnestic mild cognitive impairment associated with AT (N) classification and anosognosia</article-title><source>Neurobiol Aging</source><year>2021</year><volume>101</volume><fpage>22</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2020.12.021</pub-id><pub-id pub-id-type="pmid">33561787</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Mondragón JD, Maurits NM, De Deyn PP, Initiative ADN. Functional connectivity differences in Alzheimer’s disease and amnestic mild cognitive impairment associated with AT (N) classification and anosognosia. Neurobiol Aging. 2021;101:22–39.<pub-id pub-id-type="pmid">33561787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2020.12.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>B</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S-C</given-names></name><name name-style="western"><surname>Shim</surname><given-names>YS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J-Y</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Microstructural changes in the hippocampus and posterior cingulate in mild cognitive impairment and Alzheimer’s disease: a diffusion tensor imaging study</article-title><source>Neurol Sci</source><year>2013</year><volume>34</volume><fpage>1215</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1007/s10072-012-1225-4</pub-id><pub-id pub-id-type="pmid">23109096</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Hong YJ, Yoon B, Lim S-C, Shim YS, Kim J-Y, Ahn KJ, et al. Microstructural changes in the hippocampus and posterior cingulate in mild cognitive impairment and Alzheimer’s disease: a diffusion tensor imaging study. Neurol Sci. 2013;34:1215–21.<pub-id pub-id-type="pmid">23109096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10072-012-1225-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>AL</given-names></name><name name-style="western"><surname>Hurley</surname><given-names>SA</given-names></name><name name-style="western"><surname>Samsonov</surname><given-names>AA</given-names></name><name name-style="western"><surname>Adluru</surname><given-names>N</given-names></name><name name-style="western"><surname>Hosseinbor</surname><given-names>AP</given-names></name><name name-style="western"><surname>Mossahebi</surname><given-names>P</given-names></name><etal/></person-group><article-title>Characterization of cerebral white matter properties using quantitative magnetic resonance imaging stains</article-title><source>Brain Connect</source><year>2011</year><volume>1</volume><issue>6</issue><fpage>423</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1089/brain.2011.0071</pub-id><pub-id pub-id-type="pmid">22432902</pub-id><pub-id pub-id-type="pmcid">PMC3360545</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Alexander AL, Hurley SA, Samsonov AA, Adluru N, Hosseinbor AP, Mossahebi P, et al. Characterization of cerebral white matter properties using quantitative magnetic resonance imaging stains. Brain Connect. 2011;1(6):423–46.<pub-id pub-id-type="pmid">22432902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/brain.2011.0071</pub-id><pub-id pub-id-type="pmcid">PMC3360545</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uchida</surname><given-names>Y</given-names></name><name name-style="western"><surname>Onda</surname><given-names>K</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Troncoso</surname><given-names>JC</given-names></name><name name-style="western"><surname>Mori</surname><given-names>S</given-names></name><name name-style="western"><surname>Oishi</surname><given-names>K</given-names></name></person-group><article-title>Microstructural Neurodegeneration of the entorhinal-Hippocampus pathway along the Alzheimer’s Disease Continuum</article-title><source>J Alzheimers Dis</source><year>2023</year><volume>95</volume><issue>3</issue><fpage>1107</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.3233/JAD-230452</pub-id><pub-id pub-id-type="pmid">37638442</pub-id><pub-id pub-id-type="pmcid">PMC10578220</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Uchida Y, Onda K, Hou Z, Troncoso JC, Mori S, Oishi K. Microstructural Neurodegeneration of the entorhinal-Hippocampus pathway along the Alzheimer’s Disease Continuum. J Alzheimers Dis. 2023;95(3):1107–17.<pub-id pub-id-type="pmid">37638442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-230452</pub-id><pub-id pub-id-type="pmcid">PMC10578220</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uchida</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kan</surname><given-names>H</given-names></name><name name-style="western"><surname>Sakurai</surname><given-names>K</given-names></name><name name-style="western"><surname>Oishi</surname><given-names>K</given-names></name><name name-style="western"><surname>Matsukawa</surname><given-names>N</given-names></name></person-group><article-title>Quantitative susceptibility mapping as an imaging biomarker for Alzheimer’s disease: the expectations and limitations</article-title><source>Front Neurosci</source><year>2022</year><volume>16</volume><fpage>938092</fpage><pub-id pub-id-type="doi">10.3389/fnins.2022.938092</pub-id><pub-id pub-id-type="pmid">35992906</pub-id><pub-id pub-id-type="pmcid">PMC9389285</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Uchida Y, Kan H, Sakurai K, Oishi K, Matsukawa N. Quantitative susceptibility mapping as an imaging biomarker for Alzheimer’s disease: the expectations and limitations. Front Neurosci. 2022;16:938092.<pub-id pub-id-type="pmid">35992906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2022.938092</pub-id><pub-id pub-id-type="pmcid">PMC9389285</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uchida</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kan</surname><given-names>H</given-names></name><name name-style="western"><surname>Sakurai</surname><given-names>K</given-names></name><name name-style="western"><surname>Oishi</surname><given-names>K</given-names></name><name name-style="western"><surname>Matsukawa</surname><given-names>N</given-names></name></person-group><article-title>Contributions of blood-brain barrier imaging to neurovascular unit pathophysiology of Alzheimer’s disease and related dementias</article-title><source>Front Aging Neurosci</source><year>2023</year><volume>15</volume><fpage>1111448</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2023.1111448</pub-id><pub-id pub-id-type="pmid">36861122</pub-id><pub-id pub-id-type="pmcid">PMC9969807</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Uchida Y, Kan H, Sakurai K, Oishi K, Matsukawa N. Contributions of blood-brain barrier imaging to neurovascular unit pathophysiology of Alzheimer’s disease and related dementias. Front Aging Neurosci. 2023;15:1111448.<pub-id pub-id-type="pmid">36861122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2023.1111448</pub-id><pub-id pub-id-type="pmcid">PMC9969807</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uchida</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kan</surname><given-names>H</given-names></name><name name-style="western"><surname>Furukawa</surname><given-names>G</given-names></name><name name-style="western"><surname>Onda</surname><given-names>K</given-names></name><name name-style="western"><surname>Sakurai</surname><given-names>K</given-names></name><name name-style="western"><surname>Takada</surname><given-names>K</given-names></name><etal/></person-group><article-title>Relationship between brain iron dynamics and blood-brain barrier function during childhood: a quantitative magnetic resonance imaging study</article-title><source>Fluids Barriers CNS</source><year>2023</year><volume>20</volume><issue>1</issue><fpage>60</fpage><pub-id pub-id-type="doi">10.1186/s12987-023-00464-x</pub-id><pub-id pub-id-type="pmid">37592310</pub-id><pub-id pub-id-type="pmcid">PMC10433620</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Uchida Y, Kan H, Furukawa G, Onda K, Sakurai K, Takada K, et al. Relationship between brain iron dynamics and blood-brain barrier function during childhood: a quantitative magnetic resonance imaging study. Fluids Barriers CNS. 2023;20(1):60.<pub-id pub-id-type="pmid">37592310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12987-023-00464-x</pub-id><pub-id pub-id-type="pmcid">PMC10433620</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>